| Description |
1 online resource (xiii, 332 pages) : illustrations |
| Contents |
Intro -- Preface -- Contents -- About the Editors -- Part I: Introduction -- Chapter 1: Introduction: An Overview of Host-Directed Therapies for Tuberculosis -- Host-Directed Therapy: Purpose and History -- The Antibiotic Era -- Host Response to Mtb -- The Inflammatory Response -- Immunosupression -- Immunometabolism -- The Modern HDT Clinical Pipeline -- Conclusion -- References -- Part II: Targeting Immunometabolism -- Chapter 2: Sirtuin Deacetylases: Linking Mycobacterial Infection and Host Metabolism -- Introduction -- The Sirtuin Family -- Sirtuins, Mitochondria, and Inflammation |
|
LXR and Host Defense During Mtb Infection -- Conclusions -- References -- Part III: Enhancing Anti-mycobacterial Mechanisms -- Chapter 6: Autophagy as a Target for Host-Directed Therapy Against Tuberculosis -- Introduction -- Antibiotic Resistance in TB and the Need for Host-Directed Therapy -- Autophagy: The Conserved Cellular Process of Degradation -- Autophagy as a Defense Mechanism Against Mycobacterium tuberculosis -- Regulation of Autophagy During Mycobacterium tuberculosis Infection -- Modulation of Autophagy as Preferred Mechanisms for Survival by Mycobacteria |
|
Subversion of Autophagy by Mtb Via Targeting RNA Metabolism -- Autophagy Modulators as Therapeutic Candidates Against Tuberculosis -- Future Perspective -- References -- Chapter 7: Metformin: A Leading HDT Candidate for TB -- Introduction -- Mechanistic Targets of Metformin -- Studies Demonstrating Metformin's Anti-TB Properties -- Can Metformin Rewire Fibrotic Resolution in TB? -- Safety and Drug-Drug Interactions During Metformin Usage in TB Patients -- Conclusions -- References -- Chapter 8: Statins as Host-Directed Therapy for Tuberculosis -- Introduction |
| Summary |
This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective - thus calling for pathway/factor enhancing drugs - or maladaptive - thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases |
| Bibliography |
Includes bibliographical references |
| Notes |
Online resource; title from PDF title page (SpringerLink, viewed February 24, 2021) |
| Subject |
Tuberculosis -- Immunotherapy
|
|
Immunotherapy -- Methods
|
|
Immunotherapy
|
| Genre/Form |
Methods (Music)
|
| Form |
Electronic book
|
| Author |
Karakousis, Petros C., editor
|
|
Hafner, Richard, editor
|
|
Gennaro, Maria Laura, editor
|
| ISBN |
3030569055 |
|
9783030569068 |
|
3030569063 |
|
9783030569075 |
|
3030569071 |
|
9783030569051 |
|
